Clinical trials: Metastatic Solid Cancers
Solid Tumors
A Dose Escalation Study of OMP-54F28 in Subjects With Solid Tumors
This is an open-label Phase 1 dose escalation study of OMP-54F28 in subjects with a solid tumor for which there is no remaining standard curative therapy.
- Trial name
- NCT01608867
- Testing
- OMP-54F28
- Where
- 3 sites in United States
- Volunteers
- 26 people
- Sponsor
- OncoMed Pharmaceuticals, Inc.
Metastatic or Locally Advanced Solid Tumors
A Trial of Y101D, a PD-L1/TGF-β Bispecific Antibody, in Patients With Metastatic or Locally Advanced Solid Tumors
This is a phase 1, multicenter, open-label study to evaluate the safety, tolerability, PK, PD, immunogenicity and preliminary efficacy of Y101D in patients with metastatic or locally advanced solid tumors.
- Trial name
- NCT05028556
- Testing
- Cohort 1 of Y101D, Cohort 2 of Y101D, Cohort 3 of Y101D
- Where
- 3 sites in China
- Volunteers
- 50 people
- Sponsor
- Wuhan YZY Biopharma Co., Ltd.
Solid Tumor, Adult, Tumor, Solid
AD1208 in Subjects With Any Progressive, Locally Advanced or Metastatic Solid Tumors
The goal of this clinical trial is to evaluate the safety and tolerability of AD1208 to determine the maximum tolerated dose(MTD) or maximumly administered dose(MAD) in any progressive, locally advanced (unresectable) or…
- Conditions
- Solid Tumor, Adult, Tumor, Solid, Solid Tumor, Solid Tumor, Unspecified, Adult
- Trial name
- AD1208 (NCT06911333)
- Testing
- AD1208
- Where
- 3 sites in South Korea
- Volunteers
- 36 people
- Sponsor
- Avelos Therapeutics Inc.
Recurrent or Metastatic Cancer, Head and Neck Cancer
Safety and Efficacy of FalateScan (Technetium Tc 99m EC20) in Patients With Known Suspected Recurrent or Metastatic Cancer From a Solid Tumor
The folate receptor is over-expressed on many types of cancer cells and new folate receptor targeted therapies are being developed to target cancer cells that over-express the folate receptor.
- Conditions
- Recurrent or Metastatic Cancer, Head and Neck Cancer, Pancreas Cancer, Bladder Cancer
- Trial name
- NCT01684098
- Testing
- Tc 99m EC20
- Volunteers
- 40 people
- Sponsor
- Endocyte
Advanced Solid Tumors, Metastatic Solid Tumors
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of RAS(ON) inhibitors in combination with ivonescimab in adults with advanced or metastatic solid tumors…
- Conditions
- Advanced Solid Tumors, Metastatic Solid Tumors, Non-small Cell Lung Cancer (NSCLC), NSCLC
- Trial name
- NCT07397338
- Testing
- Daraxonrasib, Elironrasib, Zoldonrasib
- Where
- 19 sites in United States
- Volunteers
- 370 people
- Sponsor
- Revolution Medicines, Inc.
Lung Cancer, Stomach Cancer
A First-in-human Study of 3H-10000 in Patients With Unresectable or Metastatic Solid Tumors
The study is being conducted to evaluate the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of 3H-10000 in the treatment of unresectable or metastatic solid tumors .
- Trial name
- NCT07354711
- Testing
- 3H-10000
- Where
- China
- Volunteers
- 170 people
- Sponsor
- 3H Pharmaceuticals Co., Ltd.
Cancer
Study of NGR-hTNF in Combination With Doxorubicin in Solid Tumors
The main objective of the trial is to document the safety of the combination (escalation doses of NGR-hTNF, from 0.2 mcg/sqm to 1.6 mcg/sqm , with a fixed dose of doxorubicin, 75 mg/sqm).
- Trial name
- NCT00305084
- Testing
- NGR-hTNF, Doxorubicin
- Where
- 4 sites in Italy, Netherlands
- Volunteers
- 15 people
- Sponsor
- AGC Biologics S.p.A.
Malignant Solid Tumor, Metastatic Cancer
RRx-001 in Combination With Irinotecan in Metastatic or Advanced Cancer (PAYLOAD)
This is a phase 1 open-label trial to evaluate the safety, pharmacodynamics and clinical activity of RRx-001 administered in combination with irinotecan.
- Conditions
- Malignant Solid Tumor, Metastatic Cancer, Advanced Cancer
- Trial name
- PAYLOAD (NCT02801097)
- Testing
- RRx-001, Irinotecan
- Where
- 2 sites in United States
- Volunteers
- 28 people
- Sponsor
- EpicentRx, Inc.
Metastatic Solid Tumor, Recurrent Solid Tumor
A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors
The purpose of this study is to find out whether the study drug, LY4101174, is safe, tolerable and effective in participants with select advanced or metastatic solid tumors.
- Conditions
- Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm
- Trial name
- EXCEED (NCT06238479)
- Testing
- LY4101174
- Where
- 28 sites in United States, Australia and 5 more
- Volunteers
- 490 people
- Sponsor
- Eli Lilly and Company
Non-Small Cell Lung Cancer
Study of Veliparib in Combination With Nivolumab and Platinum Doublet Chemotherapy in Participants With Metastatic or Advanced Non-Small Cell Lung Cancer (NSCLC)
This study seeks to establish the recommended Phase 2 dose (RPTD) of veliparib in combination with nivolumab and platinum doublet chemotherapy (carboplatin/paclitaxel or carboplatin/pemetrexed) (Phase 1 portion) and to assess…
- Trial name
- NCT02944396
- Testing
- pemetrexed, nivolumab, paclitaxel
- Where
- 6 sites in United States
- Volunteers
- 25 people
- Sponsor
- AbbVie
Thyroid Cancer, Renal Cell Carcinoma
Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
A multicenter open-label phase 1/1b study to evaluate the safety and preliminary efficacy of nanrilkefusp alfa as monotherapy and in combination with pembrolizumab in patients with selected advanced/metastatic solid tumors
- Conditions
- Thyroid Cancer, Renal Cell Carcinoma, Non Small Cell Lung Cancer, Small-cell Lung Cancer
- Trial name
- NCT04234113
- Testing
- Nanrilkefusp alfa, Pembrolizumab
- Where
- 12 sites in United States, Czechia and 2 more
- Volunteers
- 115 people
- Sponsor
- SOTIO Biotech AG
Solid Malignancies
Study to Assess Safety, Tolerability and PK of AZD1480 in Patients With Solid Tumours
This study is being conducted to assess the safety, tolerability and PK of AZD1480 in patients with advanced solid malignancies.
- Trial name
- NCT01112397
- Testing
- AZD1480
- Where
- 3 sites in United States
- Volunteers
- 72 people
- Sponsor
- AstraZeneca
Metastatic Colorectal Cancer, Solid Tumor
A Study to Assess Safety, Efficacy, Immunogenicity, PK of GC1118 With Combination Chemotherapy
The purpose of the study is to assess the safety and tolerability of GC1118 in combination with irinotecan or FOLFIRI in order to determine the maximum tolerated dose (MTD) and the recommended phase 2 dose (RP2D)
- Trial name
- NCT03454620
- Testing
- irinotecan, FOLFIRI
- Where
- 6 sites in South Korea
- Volunteers
- 53 people
- Sponsor
- Green Cross Corporation
Advanced Cancer
Phase 1/2 Study of UI-102 in Selected Advanced Cancers
This phase 1/2 first-in-human study is designed to assess the safety and efficacy of UI-102, a TLR7/8 agonist encapsulated in a Cholesteryl Pullulan Nanoparticle.
- Trial name
- NCT07605962
- Testing
- UI-102
- Where
- 3 sites in United States
- Volunteers
- 140 people
- Sponsor
- United Immunity, co., Ltd.
Unspecified Adult Solid Tumor, Protocol Specific
GPX-100 in Treating Patients With Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of GPX-100 in treating patients who have solid tumors.
- Trial name
- NCT00003403
- Testing
- GPX-100
- Where
- 2 sites in United States
- Sponsor
- Gem Pharmaceuticals
Neoplasms
BI 6727 (Volasertib) in Combination With Cisplatin or Carboplatin in Patients With Advanced or Metastatic Solid Tumour
The primary objective of this trial is to identify the maximum tolerated dose (MTD) of BI 6727 therapy in terms of drug-related adverse events when combined with a platinum therapy (cisplatin or carboplatin).
- Trial name
- NCT00969761
- Testing
- BI-6727, BI 6727
- Where
- 2 sites in Belgium
- Volunteers
- 61 people
- Sponsor
- Boehringer Ingelheim
Solid Tumor
oHSV2-PD-L1/CD3-BsAb Administered Via Intratumoral Injection
This study will be a Phase 1, multi-center, open-label, dose escalation followed by the recommended phase 2 dose (RP2D) expansion study to characterize safety, tolerability, biodistribution, virus shedding and preliminary…
- Trial name
- NCT05938296
- Testing
- BS006 Injection
- Where
- 2 sites in United States
- Volunteers
- 29 people
- Sponsor
- Binhui Biopharmaceutical Co., Ltd.
Gastrointestinal Tumor
A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumor and Other Solid Tumor
In phase Ia study, the safety and tolerability of BL-B01D1 in patients with locally advanced or metastatic gastrointestinal tumor and other solid tumor will be investigated to determine the dose-limiting toxicity (DLT), maximum…
- Trial name
- NCT05262491
- Testing
- BL-B01D1
- Where
- 6 sites in China
- Volunteers
- 96 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Nasopharyngeal Neoplasms
Safety and Efficacy of CC-486 in Previously Treated Patients With Locally Advanced or Metastatic Nasopharyngeal Carcinoma
The purpose of this study is to evaluate the safety and efficacy of CC-486 in previously treated patients with locally advanced or metastatic nasopharyngeal carcinoma having failed one to two previous regimens, including…
- Trial name
- NCT02269943
- Testing
- CC-486
- Where
- 25 sites in United States, Canada and 7 more
- Volunteers
- 36 people
- Sponsor
- Celgene
Solid Tumors
Phase 1 Study of IBR854 in Locally Advanced Or Metastatic Solid Tumors
This study is an open-label, phase I study to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of IBR854 cell injection in patients with unresectable, locally advanced, or metastatic solid tumors.
- Trial name
- NCT06001684
- Testing
- IBR854 Cell Injection
- Where
- China
- Volunteers
- 19 people
- Sponsor
- Imbioray (Hangzhou) Biomedicine Co., Ltd.